Last reviewed · How we verify
GW685698X aqueous nasal spray
GW685698X is a selective melanin-concentrating hormone receptor 1 (MCH-R1) antagonist that reduces appetite and food intake by blocking MCH signaling in the hypothalamus.
GW685698X is a selective melanin-concentrating hormone receptor 1 (MCH-R1) antagonist that reduces appetite and food intake by blocking MCH signaling in the hypothalamus. Used for Obesity or overweight with weight-related comorbidities.
At a glance
| Generic name | GW685698X aqueous nasal spray |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | MCH receptor antagonist |
| Target | MCH-R1 (Melanin-concentrating hormone receptor 1) |
| Modality | Small molecule |
| Therapeutic area | Obesity |
| Phase | Phase 3 |
Mechanism of action
MCH is a neuropeptide that promotes feeding behavior and energy storage. By antagonizing MCH-R1 receptors in the brain, GW685698X decreases appetite signals, leading to reduced caloric intake and potential weight loss. The nasal spray formulation allows direct delivery to the central nervous system.
Approved indications
- Obesity or overweight with weight-related comorbidities
Common side effects
- Nasal irritation
- Headache
- Nausea
- Dizziness
Key clinical trials
- Study of GW685698X In Patients With Seasonal Allergic Rhinitis (PHASE3)
- Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR) (PHASE3)
- Study Of Adults And Adolescents With Vasomotor Rhinitis (PHASE3)
- Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR) (PHASE3)
- Perennial Allergic Rhinitis Study In Pediatric Subjects (PHASE3)
- Long Term Safety Of GW685698X Via Nasal Biopsy (PHASE3)
- A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR). (PHASE3)
- Study In Adults And Adolescents With Seasonal Allergic Rhinitis. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GW685698X aqueous nasal spray CI brief — competitive landscape report
- GW685698X aqueous nasal spray updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI